Cymerus (the process for producing Cynata MSCs) is more than off the shelf:
1. avoids donor to donor variability (one cell bank)
2. avoids senescense (expansion at the IPSC level, low passage)
3. IPSC MSC more potent and consistent (refer to Monash Study comparing MSC sources)
4. Replicable/scalable manufacturing
Ann: Initial Results in First 16 DFU Patients Expected in Q1 2024, page-24
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
16.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $37.28M | |||
| Open | High | Low | Value | Volume |
| 16.0¢ | 16.5¢ | 16.0¢ | $10.82K | 65.84K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 4450 | 16.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 17.0¢ | 88474 | 2 |
View Market Depth
| Last trade - 15.32pm 20/06/2025 (20 minute delay) ? |
| CYP (ASX) Chart |